Mount Sinai manages IBD for approximately 3,000 new patients every year and provides long-term follow-up for over 7,000 more at The Feinstein IBD Clinical Center. We are committed to articulating our 360-degree view of IBD both in the personalized, multidisciplinary approach we take to patient care and through the breadth and depth of our research programs. The clinical center collaborates closely with our researchers who are asking the targeted questions required to understand IBD, find treatments, and ultimately prevent the disease. This approach has enabled us to conduct various research studies such as –
· IBD Road to Prevention, which aims to prevent IBD by exploring the interplay between genetics and the microbiome. The gut microbiome is the site of IBD so studying the bacteria in the microbiome could lead to understanding what triggers the immune response that results in IBD. We will analyze samples from affected and unaffected patients, which will yield insight into the protective patterns that prevents certain people from developing IBD. The ultimate goal is individualized intervention tailored to a high-risk patient’s specific microbial fingerprint to stop the disease from emerging.
· Crohn’s Disease Observational Cohort Study – CHARIOT, is designed to examine recently diagnosed patients to improve their stratification and treatment for Crohn’s disease in its early stages. The goal of CHARIOT is to promote greater understanding of the long-term evolution of Crohn’s disease, the impact of different therapeutic strategies, and the role of predictors and biomarkers in the treatment process, and to develop accurate predictors of bowel damage and disability.
These are just two research studies of many taking place at Mount Sinai to help us uncover insights that could transform the lives of individuals affected by IBD.